Aims: A recent study conducted in mice reported that liver-specific knockout of tumor suppressor Pten augments nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcriptional activity. Here, we further investigated how phosphatase and tensin homolog deleted on chromosome 10 (PTEN) controls NRF2 and the relevance of this pathway in human carcin ogenesis. Results: Drug and genetic targeting to PTEN and phosphoproteomics approaches indicated that PTEN leads to glycogen synthase kinase-3 (GSK-3)-mediated phosphorylation of NRF2 at residues Ser335 and Ser338 and subsequent beta-transducin repeat containing protein (β-TrCP)-dependent but Kelch-like ECH-associated protein 1 (KEAP1)-independent degradation. Rescue experiments in PTEN-deficient cells and xerographs in athymic mice indicated that loss of PTEN leads to increased NRF2 signature which provides a proliferating and tumorigenic advantage. Tissue microarrays from endometrioid carcinomas showed that 80% of PTEN-negative tumors expressed high levels of NRF2 or its target heme oxygenase-1 (HO-1). Innovation: These results uncover a new mechanism of oncogenic activation of NRF2 by loss of its negative regulation by PTEN/GSK-3/β-TrCP that may be relevant to a large number of tumors, including endometrioid carcinomas. Conclusion: Increased activity of NRF2 due to loss of PTEN is instrumental in human carcinogenesis and represents a novel therapeutic target. Antioxid. Redox Signal. 21, 2498–2514.
Get full access to this article
View all access options for this article.
References
1.
AlmazariI, ParkJM, ParkSA, SuhJY, NaHK, ChaYN, SurhYJ. Guggulsterone induces heme oxygenase-1 expression through activation of Nrf2 in human mammary epithelial cells: PTEN as a putative target. Carcinogenesis, 33: 368–376, 2012.
2.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489: 519–525, 2012.
3.
ChorleyBN, CampbellMR, WangX, KaracaM, SambandanD, BanguraF, XueP, PiJ, KleebergerSR, and BellDA. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res, 40: 7416–7429, 2012.
Dinkova-KostovaAT, and WangXJ. Induction of the Keap1/Nrf2/ARE pathway by oxidizable diphenols. Chem Biol Interact, 192: 101–106, 2011.
6.
GebremedhinD, TerashviliM, WickramasekeraN, ZhangDX, RauN, MiuraH, and HarderDR. Redox signaling via oxidative inactivation of PTEN modulates pressure-dependent myogenic tone in rat middle cerebral arteries. PLoS One, 8: e68498, 2013.
7.
GobomJ, NordhoffE, MirgorodskayaE, EkmanR, and RoepstorffP. Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom, 34: 105–116, 1999.
8.
GreinerR, PalinkasZ, BasellK, BecherD, AntelmannH, NagyP, and DickTP. Polysulfides link H2S to protein thiol oxidation. Antioxid Redox Signal, 19: 1749–1765, 2013.
9.
HayesJD and Dinkova-KostovaAT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci, 39: 199–218, 2014.
10.
HenebergP. Reactive nitrogen species and hydrogen sulfide as regulators of protein tyrosine phosphatase activity. Antioxid Redox Signal, 20: 2191–2209, 2014.
11.
InnamoratoNG, RojoAI, Garcia-YagueAJ, YamamotoM, de CeballosML, and CuadradoA. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol, 181: 680–689, 2008.
12.
ItohK, ChibaT, TakahashiS, IshiiT, IgarashiK, KatohY, OyakeT, HayashiN, SatohK, HatayamaI, YamamotoM, and NabeshimaY. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun, 236: 313–322, 1997.
13.
JaramilloMC and ZhangDD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev, 27: 2179–2191, 2013.
14.
JiangT, ChenN, ZhaoF, WangXJ, KongB, ZhengW, and ZhangDD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res, 70: 5486–5496, 2010.
15.
KimYR, OhJE, KimMS, KangMR, ParkSW, HanJY, EomHS, YooNJ, and LeeSH. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol, 220: 446–451, 2010.
16.
KitagishiY and MatsudaS. Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med, 31: 511–515, 2013.
17.
KwonJ, LeeSR, YangKS, AhnY, KimYJ, StadtmanER, and RheeSG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A, 101: 16419–16424, 2004.
18.
LarsenMR, ThingholmTE, JensenON, RoepstorffP, and JorgensenTJ. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics, 4: 873–886, 2005.
19.
LauA, VilleneuveNF, SunZ, WongPK, and ZhangDD. Dual roles of Nrf2 in cancer. Pharmacol Res, 58: 262–270, 2008.
20.
LeeSR, YangKS, KwonJ, LeeC, JeongW, and RheeSG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem, 277: 20336–20342, 2002.
21.
MartinD, RojoAI, SalinasM, DiazR, GallardoG, AlamJ, De GalarretaCM, and CuadradoA. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem, 279: 8919–8929, 2004.
22.
McMahonM, ThomasN, ItohK, YamamotoM, and HayesJD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a “tethering” mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem, 281: 24756–24768, 2006.
23.
MitsuishiY, TaguchiK, KawataniY, ShibataT, NukiwaT, AburataniH, YamamotoM, and MotohashiH. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell, 22: 66–79, 2012.
24.
MuscarellaLA, ParrellaP, D'AlessandroV, la TorreA, BarbanoR, FontanaA, TancrediA, GuarnieriV, BalsamoT, CocoM, CopettiM, PellegriniF, De BonisP, BiscegliaM, ScaramuzziG, MaielloE, ValoriVM, MerlaG, VendemialeG, and FazioVM. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics, 6: 710–719, 2011.
25.
MutterGL, LinMC, FitzgeraldJT, KumJB, BaakJP, LeesJA, WengLP, and EngC. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst, 92: 924–930, 2000.
26.
NaHK and SurhYJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med, 67: 353–365, 2014.
27.
NairS, BarveA, KhorTO, ShenGX, LinW, ChanJY, CaiL, and KongAN. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin, 31: 1223–1240, 2010.
28.
NumajiriN, TakasawaK, NishiyaT, TanakaH, OhnoK, HayakawaW, AsadaM, MatsudaH, AzumiK, KamataH, NakamuraT, HaraH, MinamiM, LiptonSA, and UeharaT. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci U S A, 108: 10349–10354, 2011.
29.
OdriozolaL, SinghG, HoangT, and ChanAM. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem, 282: 23306–23315, 2007.
30.
Ortega-MolinaA, EfeyanA, Lopez-GuadamillasE, Munoz-MartinM, Gomez-LopezG, CanameroM, MuleroF, PastorJ, MartinezS, RomanosE, Mar Gonzalez-BarrosoM, RialE, ValverdeAM, BischoffJR, and SerranoM. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab, 15: 382–394, 2012.
31.
PalmeroI and SerranoM. Induction of senescence by oncogenic Ras. Methods Enzymol, 333: 247–256, 2001.
32.
Pitha-RoweI, LibyK, RoyceD, and SpornM. Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest Ophthalmol Vis Sci, 50: 5339–5347, 2009.
33.
RadaP, RojoAI, ChowdhryS, McMahonM, HayesJD, and CuadradoA. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol, 31: 1121–1133, 2011.
34.
RadaP, RojoAI, Evrard-TodeschiN, InnamoratoNG, CotteA, JaworskiT, Tobon-VelascoJC, DevijverH, Garcia-MayoralMF, Van LeuvenF, HayesJD, BerthoG, and CuadradoA. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol, 32: 3486–3499, 2012.
35.
RisingerJI, HayesAK, BerchuckA, and BarrettJC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 57: 4736–4738, 1997.
36.
RojoAI, InnamoratoNG, Martin-MorenoAM, De CeballosML, YamamotoM, and CuadradoA. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 58: 588–598, 2010.
37.
RojoAI, Medina-CamposON, RadaP, Zuniga-ToalaA, Lopez-GazconA, EspadaS, Pedraza-ChaverriJ, and CuadradoA. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic Biol Med, 52: 473–487, 2012.
38.
RojoAI, RadaP, EgeaJ, RosaAO, LopezMG, and CuadradoA. Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci, 39: 125–132, 2008.
39.
RojoAI, SagarraMR, and CuadradoA. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem, 105: 192–202, 2008.
40.
RojoAI, SalinasM, MartinD, PeronaR, and CuadradoA. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci, 24: 7324–7334, 2004.
41.
SakamotoK, IwasakiK, SugiyamaH, and TsujiY. Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell, 20: 1606–1617, 2009.
42.
SalazarM, RojoAI, VelascoD, de SagarraRM, and CuadradoA. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem, 281: 14841–14851, 2006.
SatohH, MoriguchiT, TakaiJ, EbinaM, and YamamotoM. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res, 73: 4158–4168, 2013.
45.
ShevchenkoA, WilmM, VormO, and MannM. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem, 68: 850–858, 1996.
46.
ShibataT, OhtaT, TongKI, KokubuA, OdogawaR, TsutaK, AsamuraH, YamamotoM, and HirohashiS. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A, 105: 13568–13573, 2008.
47.
SimpsonL and ParsonsR. PTEN: life as a tumor suppressor. Exp Cell Res, 264: 29–41, 2001.
SinghG and ChanAM. Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets, 11: 536–547, 2011.
50.
SolisLM, BehrensC, DongW, SuraokarM, OzburnNC, MoranCA, CorvalanAH, BiswalS, SwisherSG, BekeleBN, MinnaJD, StewartDJ, and WistubaII. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res, 16: 3743–3753, 2010.
51.
SpornMB and LibyKT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer, 12: 564–571, 2012.
52.
SprengerRR and HorrevoetsAJ. Proteomic study of caveolae and rafts isolated from human endothelial cells. Methods Mol Biol, 357: 199–213, 2007.
53.
StebbingJ, LitLC, ZhangH, DarringtonRS, MelaiuO, RudrarajuB, and GiamasG. The regulatory roles of phosphatases in cancer. Oncogene, 33: 939–953, 2014.
54.
SuzukiT, MotohashiH, and YamamotoM. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci, 34: 340–346, 2013.
TashiroH, BlazesMS, WuR, ChoKR, BoseS, WangSI, LiJ, ParsonsR, and EllensonLH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57: 3935–3940, 1997.
57.
TibarewalP, ZilidisG, SpinelliL, SchurchN, MaccarioH, GrayA, PereraNM, DavidsonL, BartonGJ, and LeslieNR. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal, 5: ra18, 2012.
58.
WangXJ, HayesJD, HigginsLG, WolfCR, and Dinkova-KostovaAT. Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. Chem Biol, 17: 75–85, 2010.
59.
XuC, YuanX, PanZ, ShenG, KimJH, YuS, KhorTO, LiW, MaJ, and KongAN. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther, 5: 1918–1926, 2006.
60.
ZhangP, SinghA, YegnasubramanianS, EsopiD, KombairajuP, BodasM, WuH, BovaSG, and BiswalS. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther, 9: 336–346, 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
